Shares of Fresenius Medical Care AG & Co. KGaA (ETR:FME) have received a consensus rating of “Buy” from the sixteen brokerages that are currently covering the company, MarketBeat reports. Six analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is €82.95 ($97.58).

Several research firms have weighed in on FME. Berenberg Bank set a €94.85 ($111.59) price target on shares of Fresenius Medical Care AG & Co. KGaA and gave the stock a “buy” rating in a research note on Monday, July 27th. Jefferies Financial Group set a €68.00 ($80.00) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Goldman Sachs Group set a €84.00 ($98.82) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a research note on Thursday, July 30th. Morgan Stanley set a €70.00 ($82.35) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a “neutral” rating in a research note on Wednesday, May 20th. Finally, Barclays set a €88.00 ($103.53) price objective on shares of Fresenius Medical Care AG & Co. KGaA and gave the company a “buy” rating in a research note on Thursday, July 30th.

Fresenius Medical Care AG & Co. KGaA stock opened at €72.56 ($85.36) on Friday. The company has a quick ratio of 0.68, a current ratio of 1.02 and a debt-to-equity ratio of 101.16. The company has a market capitalization of $22.10 billion and a PE ratio of 16.44. The firm has a fifty day simple moving average of €73.02 and a two-hundred day simple moving average of €71.08. Fresenius Medical Care AG & Co. KGaA has a twelve month low of €53.50 ($62.94) and a twelve month high of €81.10 ($95.41).

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Read More: Average Daily Trade Volume – ADTV

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.